[HTML][HTML] Circulating tumor DNA to guide rechallenge with panitumumab in metastatic colorectal cancer: the phase 2 CHRONOS trial
A Sartore-Bianchi, F Pietrantonio, S Lonardi… - Nature Medicine, 2022 - nature.com
Anti-epidermal growth factor receptor (EGFR) monoclonal antibodies are approved for the
treatment of RAS wild-type (WT) metastatic colorectal cancer (mCRC), but the emergence of …
treatment of RAS wild-type (WT) metastatic colorectal cancer (mCRC), but the emergence of …
Circulating tumor DNA to guide rechallenge with panitumumab in metastatic colorectal cancer: the phase 2 CHRONOS trial
A Sartore-Bianchi, F Pietrantonio… - Nature …, 2022 - pubmed.ncbi.nlm.nih.gov
Anti-epidermal growth factor receptor (EGFR) monoclonal antibodies are approved for the
treatment of RAS wild-type (WT) metastatic colorectal cancer (mCRC), but the emergence of …
treatment of RAS wild-type (WT) metastatic colorectal cancer (mCRC), but the emergence of …
Circulating tumor DNA to guide rechallenge with panitumumab in metastatic colorectal cancer: the phase 2 CHRONOS trial.
A Sartore-Bianchi, F Pietrantonio, S Lonardi… - Nature …, 2022 - europepmc.org
Anti-epidermal growth factor receptor (EGFR) monoclonal antibodies are approved for the
treatment of RAS wild-type (WT) metastatic colorectal cancer (mCRC), but the emergence of …
treatment of RAS wild-type (WT) metastatic colorectal cancer (mCRC), but the emergence of …
Circulating tumor DNA to guide rechallenge with panitumumab in metastatic colorectal cancer: the phase 2 CHRONOS trial
A Sartore-Bianchi, F Pietrantonio, S Lonardi… - NATURE …, 2022 - iris.unito.it
Anti-epidermal growth factor receptor (EGFR) monoclonal antibodies are approved for the
treatment of RAS wild-type (WT) metastatic colorectal cancer (mCRC), but the emergence of …
treatment of RAS wild-type (WT) metastatic colorectal cancer (mCRC), but the emergence of …
[HTML][HTML] Circulating tumor DNA to guide rechallenge with panitumumab in metastatic colorectal cancer: the phase 2 CHRONOS trial
A Sartore-Bianchi, F Pietrantonio, S Lonardi… - Nature …, 2022 - ncbi.nlm.nih.gov
Anti-epidermal growth factor receptor (EGFR) monoclonal antibodies are approved for the
treatment of RAS wild-type (WT) metastatic colorectal cancer (mCRC), but the emergence of …
treatment of RAS wild-type (WT) metastatic colorectal cancer (mCRC), but the emergence of …
Circulating tumor DNA to guide rechallenge with panitumumab in metastatic colorectal cancer: the phase 2 CHRONOS trial
A Sartore-Bianchi, F Pietrantonio, S Lonardi… - NATURE …, 2022 - air.unimi.it
Anti-epidermal growth factor receptor (EGFR) monoclonal antibodies are approved for the
treatment of RAS wild-type (WT) metastatic colorectal cancer (mCRC), but the emergence of …
treatment of RAS wild-type (WT) metastatic colorectal cancer (mCRC), but the emergence of …
Circulating tumor DNA to guide rechallenge with panitumumab in metastatic colorectal cancer: the phase 2 CHRONOS trial
A Sartore-Bianchi, F Pietrantonio, S Lonardi… - paper.sciencenet.cn
Anti-epidermal growth factor receptor (EGFR) monoclonal antibodies are approved for the
treatment of RAS wild-type (WT) metastatic colorectal cancer (mCRC), but the emergence of …
treatment of RAS wild-type (WT) metastatic colorectal cancer (mCRC), but the emergence of …